Full Year 2023 Investor Presentation
151
Investor presentation
Full year 2023
2023 statement of ESG performance
88
Novo NordiskⓇ
2023
2022
2021
Environmental
performance
Energy consumption for operations (1,000 GJ)
Share of renewable power for production sites
Scope 1 emissions (1,000 tonnes CO₂e)1
Scope 2 emissions (1,000 tonnes CO₂e) 1
Scope 3 emissions (1,000 tonnes CO₂e) 1,2
3784
3,677
3,387
100%
100%
100%
78
76
77
15
16
16
3738
2,041
NA
Water consumption for production sites (1,000 m)
4150
3,918
3,488
Waste from production sites (tonnes)
189,091
Breaches of environmental regulatory limit values
415
213,505
75
180,806
12
Patients
Patients reached with Novo Nordisk's Diabetes and Obesity care products (estimate in millions)
41.6
36.3
34.6
- Hereof reached via the Novo Nordisk Access to Insulin Commitment (estimate in millions)³
Children reached through Changing Diabetes® in Children (cumulative)
2.4
1.8
1.7
52,249
41,033
31,846
People & employees
Year-end employees (total)
64,319
55,185
48,478
Social
performance
Employee turnover
Gender in leadership positions (ratio men:women)
Gender in senior leadership positions (ratio men:women)
Gender in the Board of Directors (ratio men:women)
Sustainable Employer Score
Frequency of occupational accidents (number per million working hours)
Societies
Change in average net price across US product portfolio (% change to previous year)
Change in average net price across US insulin portfolio (% change to previous year)
Total tax contribution (DKK million)
5.5%
8.2%
11.0%
54:46
56:44
57:43
59:41
61:39
64:36
50:50
54:46
67:33
86%
85%
84%
1.5
1.5
1.3
(8.2)%
(12.7)%
(12.3)%
(24.4)%
(19.5)%
(10.9)%
51,247
36,003
32,593
Donations and other contributions (DKK million)
138
126
92
Business ethics reviews
40
35
37
Employees trained in business ethics
99%
99%
98%
Substantiated cases of corruption and bribery reported via Compliance Hotline
11
5
18
Governance
Performance
Supplier audits
Terminations of Novo Nordisk employees related to substantiated cases of corruption and bribery
Convictions for violation of anti-corruption and anti-bribery laws
19
2
13
0
N/A
N/A
382
294
253
Product recalls
2
3
1
Failed inspections
Facilitations of the Novo Nordisk Way
0
0
0
42
36
34
Company reputation (scale 0-100)
Animals purchased for research
82.1
82.3
82.6
56,508
79,750
47,879
1. 2023 is the first year of reporting all emission categories in CO₂e. Comparison figures for scope 1, 2 and part of scope 3 emissions are measured in CO2.
2022 was the first year of full scope 3 emissions' disclosure, which in 2021 and previously was limited to business flights and product distribution.
123
2.
3.
2023 is the first year of reporting Obesity as part of number of patients reached. Comparison figures are adjusted accordingly.View entire presentation